Epithelioid
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial
The Lancet Respiratory Medicine 2024 May 10 [Link] Eric Lim, David Waller, Kelvin Lau, Jeremy Steele, Anthony Pope, Clinton Ali, Rocco Bilancia, Manjusha Keni, Sanjay Popat, Mary O’Brien, Nadza Tokaca, Nick Maskell, Louise Stadon, Dean Fennell, Louise Nelson, John Edwards, Sara Tenconi, Laura Socci, Robert C Rintoul, Kelly Wood, Amanda Stone, Dakshinamoorthy Muthukumar, Charlotte Ingle,…
Read MoreMultimodal Treatment of Pleural Mesothelioma with Cytoreductive Surgery and Hyperthermic Intrathoracic Chemotherapy: Impact of Additive Chemotherapy
Cancers 2024 April 20 [Link] Laura V Klotz, Julia Zimmermann, Karolina Müller, Julia Kovács, Mohamed Hassan, Michael Koller, Severin Schmid, Gunnar Huppertz, Till Markowiak, Bernward Passlick, Hans-Stefan Hofmann, Hauke Winter, Rudolf A Hatz, Martin E Eichhorn, Michael Ried Abstract Cytoreductive surgery (CRS) combined with hyperthermic intrathoracic chemoperfusion (HITOC) is a promising treatment strategy for pleural…
Read MoreEvaluation of first-line and salvage therapies for unresectable malignant mesothelioma: A systematic review and network meta-analysis
Critical Reviews in Oncology and Hematology 2024 April 26 [Link] Wei Zhuang, Lihui Liu, Boyang Sun, Hua Bai, Zhijie Wang, Jianchun Duan, Rui Wan, Zixiao Ma, Jia Zhong, Jie Wang Abstract Background: Randomized controlled trials (RCTs) of systemic therapies for unresectable malignant mesothelioma have reported conflicting results. It is crucial and urgent to find optimal…
Read MoreImpact of guideline therapy on survival of patients with stage I-III epithelioid mesothelioma
Journal of Thoracic Disease 2023 December 30 [Link] Douglas Z Liou, Yoyo Wang, Prasha Bhandari, Joseph B Shrager, Natalie S Lui, Leah M Backhus, Mark F Berry Abstract Background: Modern treatment guidelines recommend multimodal therapy with at least chemotherapy and surgery for patients with potentially resectable epithelioid mesothelioma. This study evaluated guideline compliance for patients…
Read MoreReflecting real-world patients with mesothelioma in research: an interim report of baseline characteristics from the ASSESS-meso cohort
ERJ Open Research 2023 December 27 [Link] Ruairi J H Conway, Natalie Smith, William Cooper, Geraldine Lynch, Sonia Patole, Jenny Symonds, Anthony Edey, Nick A Maskell, Anna C Bibby Abstract Objective: Mesothelioma varies in clinical phenotype and survival. Clinical trials are unavoidably affected by selection bias, reducing generalisability. ASSESS-meso is a UK, multicentre, prospective, mesothelioma…
Read MoreExtensive Skeletal Muscle Metastases in Malignant Pleural Mesothelioma Detected by FDG PET/CT
World Journal of Nuclear Medicine 2023 December 4 [Link] Mustafa Yilmaz, Ozan Kandemir, Ediz Tutar Abstract Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor originating from pleural mesothelial cells. Distant skeletal muscle metastasis is rare in MPM. A 54-year-old woman was diagnosed with epithelioid MPM and treated with surgery, chemotherapy, and radiotherapy 2…
Read MoreMethylthioadenosine Phosphorylase and Breast Cancer 1 Protein-Associated Protein 1 as Biomarkers for the Peritoneal Mesothelioma
Cancer Control 2023 January-December [Link] Yue Chen, Xuemei Du, Ying Gao, Heliang Wu, Hongyu Zhao, Yandong Su Abstract Objectives: Combination of Breast Cancer 1 protein-associated protein 1 (BAP1) and methylthioadenosine phosphorylase (MTAP) in the peritoneal mesothelioma (PeM) has yet to be explored. We aim to assess the diagnostic value of combined BAP1 and MTAP to…
Read MoreValidation of a Gene Expression Approach for the Cytological Diagnosis of Epithelioid and Biphasic Pleural Mesothelioma on a Consecutive Series
Cancers 2023 November 22 [Link] Rossella Bruno, Anello Marcello Poma, Greta Alì, Agnese Proietti, Alessandro Ribechini, Antonio Chella, Gabriella Fontanini Abstract Cytological diagnosis of pleural mesothelioma (PM) is controversial, even using ancillary markers (BAP1, MTAP and CDKN2A). Here, we aimed to prospectively validate a previously developed 117-gene expression panel for the differential cytological diagnosis of…
Read MorePhase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299
JTO Clinical and Research Reports 2023 October 12 [Link] Arkadiusz Z Dudek 1 2, Min X Xi 1, Katherine A Scilla 3, Hirva Mamdani 4, Benjamin C Creelan 5, Andreas Saltos 5, Tawee Tanvetyanon 5, Alberto Chiappori Abstract Introduction: We hypothesized that ramucirumab could increase previously reported objective response rate (ORR) of 11% of single-agent…
Read MoreRandomized trial of intravenous versus bidirectional chemotherapy after cytoreductive surgery for malignant peritoneal mesothelioma
International Journal of Surgical Protocols 2023 September 26 [Link] Paul H Sugarbaker Abstract Background: Malignant peritoneal mesothelioma (MPM) is a rare disease that progresses within the peritoneal cavity and only disseminates to systemic sites in the terminal months of the disease. For this malignancy, there are several regimens of chemotherapy that have been accepted as…
Read More